Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.78 |
| ▸ | MC5R | P33032 | 2/20 | 0.78 |
| ▸ | MC3R | P41968 | 2/20 | 0.78 |
| ▸ | MC1R | Q01726 | 2/20 | 0.78 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.73 |
| ▸ | CTSL | P07711 | 3/20 | 0.66 |
| ▸ | CTSS | P25774 | 3/20 | 0.66 |
| ▸ | CTSK | P43235 | 3/20 | 0.66 |
| ▸ | CTSH | P09668 | 1/20 | 0.66 |
| ▸ | GLP1R | P43220 | 4/20 | 0.64 |
| ▸ | GCGR | P47871 | 3/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.61 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.59 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533733 | 0.98 | MC4R (0.78) | MC4RMC5RMC3RMC1RC5AR1 | |
| Codactide SCHEMBL29409825 | 0.98 | MC4R (0.74) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29533861 | 0.98 | C5AR1 (0.74) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL18388638 | 0.97 | C5AR1 (0.74) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29973172 | 0.97 | C5AR1 (0.77) | MC4RMC5RMC3RMC1RC5AR1 | |
| Intermedine SCHEMBL20548027 | 0.96 | MC4R (0.82) | MC4RMC5RMC3RMC1RC5AR1 | |
| Intermedine SCHEMBL22076809 | 0.96 | MC4R (0.82) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29358645 | 0.96 | MC4R (0.82) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL30017682 | 0.96 | C5AR1 (0.77) | MC4RMC5RMC3RMC1RC5AR1 | |
| Cosyntropin SCHEMBL720535 | 0.96 | C5AR1 (0.74) | MC4RMC5RMC3RMC1RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057914-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240398891-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2024-12-05 | — | — | US | disclosed |
| US-11576987-B2 | Compositions and methods of treating melanoma | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220111080-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220072092-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057914-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | MC1R, TIE1, RB1 | MC4R 189/4885MC5R 58/4885MC3R 69/4885 |
| US-20240398891-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | MC1R, TIE1, RB1 | MC4R 184/4885MC5R 57/4885MC3R 69/4885 |
| US-20220072092-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | MC1R, TIE1, RB1 | MC4R 189/4885MC5R 58/4885MC3R 69/4885 |
| US-11576987-B2 | Compositions and methods of treating melanoma | MC1R, TIE1, RB1 | MC4R 190/4885MC5R 62/4885MC3R 67/4885 |
| US-20220111080-A1 | COMPOSITIONS AND METHODS OF TREATING MELANOMA | MC1R, TIE1, RB1 | MC4R 190/4885MC5R 62/4885MC3R 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.